Biotechnology - Rare diseases, Financial


Current filters:

Rare diseasesFinancial

Popular Filters

Hawaii Biotech awarded $5.5million government grant for botulism therapy

Hawaii Biotech awarded $5.5million government grant for botulism therapy


Privately-held US biotech company Hawaii Biotech has been awarded a contract to continue developing drugs…

BiotechnologyFinancialHawaii BiotechRare diseasesResearchUSA

arGEN-X reaches two milestone payments in Shire deal and signs research agreement with Boehringer


Belgium-based biotech firm arGEN-X has reached two important success milestones in its SIMPLE Antibody…

arGEN-XBelgiumBiotechnologyBoehringer IngelheimFinancialGeneticsLicensingRare diseasesResearchShire

Agilis Biotherapeutics and Intrexon collaborate on rare genetic disease


US synthetic biology companies Agilis Biotherapeutics and Intrexon have entered an exclusive channel…

Agilis BiotherapeuticsBiotechnologyBoardroomFinancialIntrexonManagementRare diseasesResearch

Big news day for Amicus, with change in GSK deal, an acquisition and restructuring

Big news day for Amicus, with change in GSK deal, an acquisition and restructuring


US biotech firm Amicus Therapeutics saw its shares fall 4.2% to $2.03 by mid-morning trading on Thursday,…

Amicus TherapeuticsBiotechnologyCallidus BiopharmaFinancialGlaxoSmithKlineLicensingManagementMergers & AcquisitionsmigalastatRare diseases

Isis Pharma earns $10 million milestone in deal with Biogen


Isis Pharmaceuticals says that it has earned a $10 million milestone payment from fellow USA-based biotech…

Biogen IdecBiotechnologyFinancialIsis PharmaceuticalsISIS-DMPKrxRare diseasesResearch

Genzyme to invest $80 million to expand capacity for Fabrazyme

Genzyme to invest $80 million to expand capacity for Fabrazyme


French drug major Sanofi’s US biotech subsidiary Genzyme says that it is investing $80 million to build…

BiotechnologyFabrazymeFinancialGenzymeNorth AmericaProductionRare diseasesSanofi

Isis earns milestone payments from GlaxoSmithKline

Isis earns milestone payments from GlaxoSmithKline


US biotech firm Isis Pharmaceuticals says that UK pharma giant GlaxoSmithKline has added a development…

BiotechnologyFinancialGlaxoSmithKlineIsis PharmaceuticalsLicensingPharmaceuticalRare diseases

Easier access to funded enzyme replacement therapy proposed in New Zealand


New Zealand’s Pharmaceutical Management Agency PHARMAC is providing greater funded access to the expensive…

Asia-PacificBiotechnologyFinancialGenzymeRare diseasesRelvar ElliptaSanofi

iPierian secures funding for launch of spin-out, True North Therapeutics


US biotech firm iPierian says that a new financing of $30 million has been secured to continue to advance…

BiotechnologyFinancialiPierianIPN007NeurologicalRare diseasesResearchTrue North Therapeutics

The case for Insmed's CF drug candidate Arikace; analysts' views


The 16% decline in US biotech firm Insmed's (Nasdaq CM: INSM) stock is an overreaction to results from…

ArikaceBiotechnologyFinancialInsmedRare diseasesRegulationResearchRespiratory and Pulmonary

European Medicines Agency simplifies processing of fee reductions for orphan medicines


The European Medicines Agency has cancelled the procedure by which sponsors of medicines with an orphan…

BiotechnologyEuropeFinancialPharmaceuticalRare diseasesRegulation

Orphan diseases' appeal lies in return on investment, says Evaluate


For many years, Big Pharma's model of success has been the blockbuster: drugs that sell more than $1…

BiotechnologyFinancialMarkets & MarketingPharmaceuticalRare diseasesResearch

Merck Serono's EPP funds EspeRare Foundation, which will reposition rimeporide


Merck Serono, the biotech unit of Germany's Merck KGaA (MRK: DE) has announced the launch of the EspeRare…

BiotechnologyEspeRare FoundationFinancialMerck KGaAMerck SeronoPharmaceuticalRare diseasesResearchrimeporide

Rare diseases research gets 144 million-euro funding from European Commission


On Rare Disease Day 2013 (February 28), the European Commission announced 144 million euros ($189.5 million)…

BiotechnologyEuropeFinancialPharmaceuticalRare diseasesResearch

EMA updates on fee reduction for SMEs developing orphan drugs in 2013


The European Medicines Agency's policy on fee reductions for orphan medicinal products is set to continue…

BiotechnologyEuropeFinancialPharmaceuticalRare diseasesRegulation

Pharming gets $10 million milestone from Santarus on Ruconest progress


Loss-making Dutch biotech company Pharming Group NV (NYSE Euronext: PHARM) said yesterday that, following…

BiotechnologyFinancialPharmingRare diseasesResearchRuconestSantarus

Biogen Idec sells Benlysta royalty rights to DRI for initial $18.3 million


US biotech firm Biogen Idec (Nasdaq: BIIB) has sold to a Canada-based DRI Capital managed fund its royalty…

BenlystaBiogen IdecBiotechnologyFinancialGlaxoSmithKlineHuman Genome SciencesLicensingPharmaceuticalRare diseases

Cell Therapeutics prepares for Pixuvri launch; posts 2nd-qtr results


US biotech firm Cell Therapeutics (Nasdaq: CTIC) yesterday reported second-quarter 2012 financial results…

BiotechnologyCell TherapeuticsFinancialMarkets & MarketingOncologypacritinibPixuvriRare diseasesResearchtosedostat

EMA approves Shire Vpriv plant in USA


Ireland-headquartered biopharma firm Shire (LSE: SHP) says that the European Medicines Agency's Committee…

BiotechnologyFinancialNorth AmericaPharmaceuticalRare diseasesRegulationReplagalShireVpriv

Prosensa raises 23 million euros


Prosensa, the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases…

BiotechnologyFinancialProsensaRare diseasesResearch

Human Genome Sciences’ Benlysta sales disappoint


US biotech firm Human Genome Sciences (Nasdaq: HGSI) president and chief executive Thomas Watkins yesterday…

BenlystaBiotechnologyFinancialHuman Genome SciencesMarkets & MarketingRare diseasesraxibacumab

Prosensa to get milestone payments from GSK under Duchenne collaboration


Dutch biotech company Prosensa, focusing on rare diseases with an unmet medical need, has agreed with…

BiotechnologyFinancialGlaxoSmithKlineLicensingPharmaceuticalProsensaRare diseasesResearch

Company Spotlight



Back to top